Home > Boards > US Listed > Biotechs >

Regen Preferred (RGBPP)

RGBPP RSS Feed
Add RGBPP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, mick
Search This Board: 
Last Post: 7/29/2020 9:32:25 AM - Followers: 48 - Board type: Free - Posts Today: 0


https://www.regenbiopharmainc.com/


Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials.
Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. 
The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax),
modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS),
and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

2018-NEWS;
February 21, 2018 | SOURCE: PRNewswire | Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the
three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to it.
The object of this structure-determination program is to shed light on how the small molecules bind to and modulate NR2F6 activity.
DOWNLOAD>>>

January 17, 2018 | SOURCE: PRNewswire | Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element
whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization.
DOWNLOAD>>>
 

2017
November 27, 2017 | SOURCE: PRNewswire | Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the
Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats.
Key attributes that are being measured include pH, plasma and liver microsomal stability, along with pharmacokinetics.
DOWNLOAD>>>

November 16, 2017 | SOURCE: PRNewswire | Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system.
Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.
DOWNLOAD>>>

November 8, 2017 | SOURCE: PRNewswire | Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.
In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
DOWNLOAD>>>

October 30, 2017 | SOURCE: PRNewswire | Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB).
The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB.
The advisory board will assist Regen's management team in evaluating partnership and licensing opportunities related to the company's intellectual property including its NR2F6 program.

https://www.regenbiopharmainc.com/products.html
https://www.regenbiopharmainc.com/company-news.html

 

DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.

 








 
RGBPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGBPP News: Current Report Filing (8-k) 01/22/2020 04:05:41 PM
RGBPP News: Current Report Filing (8-k) 01/07/2020 04:35:27 PM
RGBPP News: Current Report Filing (8-k) 12/18/2019 10:49:56 AM
RGBPP News: Current Report Filing (8-k) 11/18/2019 05:17:21 PM
RGBPP News: Quarterly Report (10-q) 10/24/2019 02:42:35 PM
PostSubject
#1725   $RGBPP NEEDS SOME NEWS mick 07/29/20 09:32:25 AM
#1724   crazy for sure gotinearly 07/29/20 08:35:11 AM
#1723   mick, what do you think gotinearly 07/29/20 08:34:33 AM
#1722   would love to know if anybody has heard gotinearly 07/29/20 08:33:57 AM
#1721   interesting this thing seems to still have a gotinearly 07/29/20 08:33:19 AM
#1720   Preying on the despondent owners of pets suffering SanDiegoAlan 07/28/20 05:06:11 AM
#1719   $RGBPP Regen Biopharma Inc (RGBPP) mick 07/25/20 01:53:18 PM
#1718   Sister ZANDER just granted PATENT re dogs/cancer. ronrooster 07/22/20 02:47:33 PM
#1717   Regen Biopharma Inc (RGBPP) mick 07/16/20 11:36:54 PM
#1716   Regen Biopharma Inc (RGBPP) mick 06/29/20 11:38:37 PM
#1715   Record volume today,almost 5 million,some big selling.Maybe Mick ronrooster 06/22/20 06:42:44 PM
#1714   Regen Biopharma Inc (RGBPP) mick 06/07/20 01:42:37 PM
#1713   Regen Biopharma Inc (RGBPP) mick 05/28/20 12:56:17 AM
#1712   Regen Biopharma Inc (RGBPP) mick 05/08/20 04:22:51 PM
#1711   Regen Biopharma Inc (RGBPP) mick 05/05/20 02:40:31 PM
#1710   https://otcbb.swingtradebot.com/equities/RGBPP mick 04/25/20 01:06:47 PM
#1709   8 day-50 day-200 day-https://www.barchart.com/stocks/quotes/RGBPP/technical-chart mick 04/13/20 11:43:41 AM
#1708   Purchase price of .05ish a share ya think? Cd1414 03/31/20 06:47:22 PM
#1707   has paul been a problem here for awhile? koolmc 03/31/20 01:36:30 PM
#1706   News in Bmsnd! Read it! lab40 03/30/20 04:27:04 PM
#1705   Just noticed Mick is now the moderator for ronrooster 03/27/20 02:12:53 PM
#1704   mick has nice little scam going,Simply get some ronrooster 03/27/20 01:34:51 PM
#1703   Regen Biopharma Inc (RGBPP) mick 03/27/20 12:19:32 PM
#1702   Most aren't even relevant! lab40 03/27/20 11:55:06 AM
#1701   Mick,what is the purpose of all your non ronrooster 03/27/20 10:33:43 AM
#1700   https://www.regenbiopharmainc.com/ mick 03/26/20 04:32:29 PM
#1699   https://www.otcmarkets.com/stock/RGBPP/security mick 03/26/20 03:55:38 PM
#1698   https://www.otcmarkets.com/stock/RGBPP/profile mick 03/26/20 03:55:14 PM
#1697   https://www.otcmarkets.com/stock/RGBPP/overview mick 03/26/20 03:54:35 PM
#1696   https://www.otcmarkets.com/stock/RGBPP/overview mick 03/26/20 03:54:11 PM
#1695   Regen Biopharma Inc (RGBPP) mick 03/26/20 03:53:46 PM
#1692   13 G out REGEN PREFERRED SHARES.LG CAPITAL FUNDING, ronrooster 03/03/20 11:36:17 AM
#1690   that coward bastard that's not enough jhenmal 01/22/20 05:13:23 PM
#1689   WOOT! bout time. trazbull 01/22/20 04:30:57 PM
#1688   BIG NEWS, KOOS RESIGNED!! ronrooster 01/22/20 04:14:44 PM
#1687   I HOPE THEY TAKE EVERTHING THAT FOOL jhenmal 01/20/20 11:31:34 AM
#1686   Zander,Regen etc being sued for 1.2 m outstanding ronrooster 01/07/20 04:58:18 PM
#1685   Giving Koos 60mill is a mistake! Rgbpp lab40 09/20/19 05:58:58 PM
#1683   https://www.sec.gov/Archives/edgar/data/1718644/000160706219000365/zander091819f gotinearly 09/19/19 08:29:00 AM
#1682   RGBPP AMG 08/07/19 10:43:57 PM
#1681   Dead. belgiumsui 08/07/19 01:32:34 PM
#1680   Why large volume for RGBP only ??? ron51ron51 03/01/19 10:11:01 AM
#1679   Dead message board, dead money. SanDiegoAlan 01/23/19 02:32:44 PM
#1677   LOL archer111 11/30/18 07:08:08 PM
#1676   LOL archer111 11/30/18 07:07:59 PM
#1675   In. AJ TonyJoe1957 11/13/18 03:00:54 PM
#1674   So predictable here they suck you in and jhenmal 11/02/18 02:12:53 PM
#1673   Probably not til Friday. Better load the boat EDMGUY 10/30/18 03:15:50 PM
#1672   SO when is this going to get to SidVicious 10/30/18 02:38:42 PM
#1671   Wouldn't touch the preferred with a ten foot SanDiegoAlan 10/23/18 04:02:20 AM
PostSubject